Pay in 4 interest-free payments of $124.38 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
in addition to AT&T and Boeing
To put the report together
successful drug: How a negative readout can lead to FDA approval
Food and Drug Administration’s approach to regulating viral vector therapies
Once you have
The STAT user’s guide to venture capital in biotech License Type:Individual in addition to AT&T andPublished: Oct. 2019 This 140 page report profiles over 50 venture capital firms that invest in biotechnology from firms that specialize in biotech (or in health care in general), to generalists who are pumping money into the broader technology sector, with biotech as part of the mix. This is an ideal report for startups looking to raise venture capital, and to navigate the field of opportunity from coast to coast. Highlights include: Nine deep dives
